Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan

THOUSAND OAKS, Calif. and TOKYO, July 13, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo; TSE: 4568) today announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several… http://www.prnewswire.com/news-releases/amgen-and-daiichi-sankyo-announce-agreement-to-commercialize-biosimilars-in-japan-300298431.html